Prescient Therapeutics (ASX:PTX) has dosed the first patient in its phase 2a clinical study of cancer treatment candidate PTX-100, a compound with the ability to block an important cancer growth enzyme, according to a Tuesday filing with the Australian bourse.
The study will evaluate two dosage levels of PTX-100 in about 40 patients with relapsed/refractory cutaneous T-cell lymphoma on an open-label basis. Its primary endpoint is efficacy, with safety as part of the secondary endpoints, the filing said.
Company shares rose 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.